JAMA : the journal of the American Medical Association
-
Randomized Controlled Trial Multicenter Study
Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease: Three Randomized Clinical Trials.
New therapeutic approaches for Alzheimer disease (AD) are needed. ⋯ In patients with mild to moderate AD, the use of idalopirdine compared with placebo did not improve cognition over 24 weeks of treatment. These findings do not support the use of idalopirdine for the treatment of AD.